Merion Road Capital Management and Blue Hill Advisors urge United Bancorporation of Alabama to return excess capital, improve profitability, and strengthen corporate governance

Merion Road Capital Management and Blue Hill Advisors urged United Bancorporation of Alabama (UBAB) to act on its excess capital and improve operations, arguing recent results have been “underwhelming.” They cite valuation at $55.36/share (1.18x TBV; 0.71x adjusted TBV; 9.4x LTM earnings) and propose a modified Dutch auction reverse tender offer to repurchase up to $40M of shares, estimating ~22% earnings and ~6% adjusted TBV accretion. The letter also highlights deposits contracting since 2022 (-0.9% CAGR) and operating expenses rising 46% with expense guidance raised by 40% over two years, pressuring management and the board on credibility and governance.

Analysis

This is more of a balance-sheet efficiency story than a fundamental turnaround. If management is forced to return capital, the market will likely re-rate UBAB on a lower-share count and higher ROE, but the bigger implication is that excess capital is now an embedded source of activism risk across small ECIP banks and other thinly deployed balance sheets. The first-order beneficiary is UBAB equity; the second-order winners are similar names where buyback optionality can substitute for growth, especially in a slower deposit environment.

The near-term catalyst is not earnings but governance: board response, any engagement with Treasury, and whether the company signals a concrete capital plan within the next 1-2 quarters. If the company delays, the stock can stay cheap because liquidity is poor and the market will discount activist letters that do not lead to a proxy threat. Over 6-18 months, the key question is whether capital return can offset stalled deposit creation; if not, the multiple should remain capped even after a tender.

The contrarian angle is that the activist may be overestimating how easily capital can be monetized. Treasury approval, regulatory conservatism, and any hidden asset-quality or funding concerns can constrain distributions, and a tender at a premium could be value-destructive if deposit attrition accelerates afterward. In that case, the right trade is not simply 'buy cheap bank,' but 'buy the stock only if there is an announced process,' otherwise wait for confirmation and avoid paying for optionality that may never be exercised.

Key Decisions for Investors

• Watchlist: UBAB as a catalyst-driven special situation; initiate only on a signed board response or announced tender/dividend framework. Upside is likely 15-25% on a credible buyback path, but without that, the stock can remain trapped at a low multiple for months.
• Relative-value idea: long UBAB / short KRE or a regional-bank basket if liquidity allows, betting that any capital return announcement re-rates UBAB faster than the sector. Use this only after volume confirms that the market can absorb position size; otherwise slippage will overwhelm edge.
• Long-only trigger: buy UBAB on an announced tender below or near tangible book with a clear post-transaction CET1 floor. Falsifier: any filing or guidance implying Treasury/regulatory resistance, or a board statement that capital will remain idle while M&A is “evaluated.”
• Sector watch: monitor similar excess-capital/ECIP names (BFCC, BYFC, CZBS, MFBP, MNMB, NMBF, PDLB, SFDL) for copycat activism. A successful UBAB outcome could compress discounts across the group by signaling that buybacks are now politically feasible.
• No trade recommendation on M or TGT from this item alone; the only actionable spillover is in regional-bank capital return optics, not retail or consumer demand.